Europe Home Infusion Therapy Market

Market Overview

The Europe Home Infusion Therapy Market was valued at approximately USD 8.4 billion in 2024 and is projected to reach USD 15.1 billion by 2033, growing at a CAGR of 6.8% during the forecast period (2025–2033).

Home infusion therapy is the intravenous or subcutaneous delivery of drugs or biologics in the home setting, allowing patients to be treated in their homes for a variety of conditions to include infections, cancer, nutritional deficits, and chronic illnesses, rather than being hospitalized for longer periods. Home infusion therapy utilizes infusion pumps, IV sets, and other related devices, along with home care nurses and clinical monitoring. This market is currently on the rise in Europe as a result of the increased aging population, burden of chronic illness, and the increased need for economically feasible and more convenient modalities of care. In addition, regulatory changes involving infusion technologies and portable devices and digital remote monitoring devices are improving safety and usability of therapies provided in the home. Since reimbursement policies for home infusion therapy have been favorable in countries like Germany and the UK as a permanent service, it continues to accelerate and has firmly established itself as a viable form of modern outpatient care in European markets.

Market Dynamics

Market Drivers

Growing Burden of Chronic Diseases and Rising Preference for Home-Based Care

The increasing number of chronic diseases such as cancer, diabetes, congestive heart failure, and immune deficiencies represents a primary driver for the Europe home infusion therapy market. Such diseases can require long-term and/or recurring infusion-based treatments, and more care is being moved home to reduce the burden on hospitals, and increase patient comfort.

For example, the European Cancer Information System (ECIS) recently estimated that over 2.7 million people in the EU were diagnosed with cancer in 2023 and that chemotherapy represents a significant component of treatment. Traditionally, chemotherapy was administered in a hospital, however, the practice has since transferred to infusing at home using ambulatory infusion pumps so that oncology clinics are not overloaded with patients, and patients can feel a sense of quality of life while undergoing treatment.

Also, diabetes management using an infusion of insulin has become seamless using portable infusion pumps/wearable infusion devices for those with Type 1 Diabetes, and in 2023, the International Diabetes Federation (IDF) calculated that there were over 61 million adults in Europe living with diabetes, driving the need for more home-based endocrinology infusion solutions.

Many health systems in Europe have established policies to incentivise home-based care as an alternative to continued hospital admissions, such as the National Health Service (NHS)’s policy in the United Kingdom and the statutory health insurance (SHI) policy in Germany, and with such policies in place for sustainable cost savings, infusions at home is certainly on the rise.

Advancements in Infusion Technologies and Supportive Reimbursement Policies

Technological innovation is changing the direction of home infusion therapy in Europe, leading to safer, more accurate and user-friendly drug administration outside the clinical environment. Smart infusion pumps with capabilities to connect via Bluetooth, as well as remote monitoring and programmable dosing features, have improved the efficacy and safety of home-based treatment.

For example, Fresenius Kabi as well as B. Braun have produced portable infusion devices that allow real-time sharing of data and provide the clinician with the ability to monitor the patient remotely, which produces less risk and better health outcomes. Remote monitoring is essential in the case of complex therapies, such as total parenteral nutrition (TPN) and antibiotic infusions, wherein dosing has to be precise.

An enabling reimbursement system is reinforcing the home infusion therapy market.  Countries such as Germany and the Netherlands have clear reimbursement mechanisms that cover the costs of home infusion therapy, with public insurance schemes encouraging healthcare providers and patients to adopt home care models.

Likewise, in France by expanding the “Hospital at Home” (HAD) initiative, the government has expanded reimbursements for home-based provision of services such as antibiotic infusion, hydration therapy and palliative care. All of these reimbursement policies are intended to improve a patient’s out-of-pocket costs while providing an incentive for providers to develop the appropriate infrastructure and services to meet patient needs.

Market Restraints

Rising Aging Population and Increased Demand for Long-Term Care at Home

The value of home infusion therapy is being driven by Europe’s aging demographic. As people age, the likelihood of acquiring a chronic or degenerative disease such as cancer, diabetes, cardiovascular diseases and gastrointestinal complications increases significantly which in many cases requires infusion-based therapy either frequently or continuously.

Home infusion therapy represents a viable option for elderly patients, who might otherwise have problems with mobility and may want to avoid hospitalization due to the risk of having an infection, not to mention the high cost. According to Eurostat, in 2023, more than 21% of the population across the European Union was aged 65+, with that figure projected to reach almost 30% by 2050.

In %%% would be the largest, if not the largest by population of national markets for home healthcare services, over 24% of Germany’s population is now over 65. This demographic trend is contributing directly to the increase in opportunities for in-home treatment services include hydration therapy, parenteral nutrition infusion, and pain management infusions, especially in the case of terminal or palliative care.

Segmental Analysis

The Europe Home Infusion Therapy Market is segmented by type and application. Each segment contributes uniquely to improving patient care, reducing hospital stays, and enhancing treatment outcomes in home-based healthcare.

By Product

Products accounted for the largest segment in Europe home infusion therapy in 2024. This segment is leading growth due to increasing use of advanced infusion pumps, intravenous sets and needleless connectors that help safely and effectively deliver medication at home. Infusion pumps, like electronic pumps and ambulatory pumps, are in high demand due to the precision of their work and their addition to complex drug regimes that allow patients to remain in the home instead of a hospital.

Growing use of technology, including features of smart pumps that have remote monitoring and tracking capabilities, are further driving product based growth. The services segment is also rapidly increasing because more clients of home infusion therapy need professional providers to help deliver infusion therapy in the home.

The services will include drug compounding, patient training and clinical monitoring which will support adherence to complex medications, like chemotherapy, and parenteral nutrition and monitor drug side effects. As healthcare shifts across Europe from coordinated acute and chronic care to decentralized care, the demand for coordinated home infusion therapy services increases steadily.

By Application

Anti-infective therapy represented the largest share of the market in 2024, due to the large-scale uptake of intravenous antibiotics, for the treatment of severe infections in the community. Anti-infective therapy in the home reduces hospital admissions, improves the comfort level of patients, particularly in the case of chronic infections or after routine surgery.

The rise of multi-drug resistant infections has added to the emphasis on long-term anti-infective therapy in the home. The chemotherapy segment is growing the fastest due to the increase of cancer patients and movement to outpatient care in oncology. The home infusion of chemotherapy agents allows patients to still experience quality of life while receiving important therapies.

This segment is currently moving quickly in Germany and the UK, where home-based models of cancer care are being expanded. Parenteral and enteral nutrition are also sizeable = components of the market, especially for patients with gastrointestinal dysfunction or nutritional deficiency (with enteral nutrition expected to be the fastest growing segment of the home nutrition market).

These segments have benefits associated with a growing understanding of nutritional therapy and modes of delivery for infusion. Hydration therapy and endocrinology applications (including insulin infusion for diabetes) round out the market and indicate the breadth of use cases for home infusion in the chronic disease space across Europe.

Regional Analysis

North America

In 2024, North America will be the largest market globally accounting for 41.2% driven by one of the most developed healthcare infrastructures, continuous acceptance of home-based medical services and the increasing burden of chronic conditions, including cancer and diabetes.

The United States is likely to continue contributing the most to this market because of strong insurance coverage for home infusion services supported through Medicare and private payers. Companies such as Option Care Health and Baxter are developing and expanding integrated home infusion networks. The increased ageing population and continual efforts to lower hospital re-admission rates will continue to support demand in this region.

Europe

Europe is the second largest market in terms of contributions from key countries, including Germany, the United Kingdom, France, Italy, and Spain. In 2024, Europe represented approximately 27.4% of the global market. The drivers of growth in this region are the increase in chronic diseases, reimbursement, and government initiatives fostering home healthcare.

For example, the French “Hospitalisation à domicile” (HAD) program, and mandatory insurance in Germany both fuelled implementation of home therapies including home chemotherapies and parenteral nutrition. The graying population and demand for affordable care are also leading the charge.

Asia-Pacific

The Asia-Pacific region is forecast to grow the fastest at a CAGR of 8.7% due to increasing healthcare spending as countries are improving their homecare structure and the proportion of geriatric populations continue to grow in markets such as China, Japan and India. For example, in Japan, the government funds and promotes home-based medical services through the establishment of community-based integrated care systems and in India awareness of the healthcare system is increasing alongside a growing private healthcare sector to improve the availability of home infusion solutions. Urbanization and diabetes and cancer prevalence are also contributing to this region’s growth.

Latin America and Middle East & Africa

Moderate growth is occurring in the Latin America and Middle East & Africa regions, driven by increased investments in healthcare infrastructure and expansions of patients seeking more outpatient and home-based care. Brazil and Mexico are developing their homecare capabilities and expanding services, especially catering to their elderly and chronically ill patients.

Market access challenges for trained healthcare professionals, continuity of care with fragmented reimbursement systems in each of these markets, and economic inequities for patients will continue to create challenges. In the Middle East, United Arab Emirates (UAE) and Saudi Arabia are scaling their initiatives to make home health services more widespread, but they still have significantly less market penetration than in the developed regions of the world.

Recent Developments

1. April 2025: Fresenius Kabi launched its latest portable infusion pump, the “Fresenius Pump X1,” featuring enhanced Bluetooth connectivity and remote monitoring capabilities for improved patient safety and clinician oversight.
2. February 2025: B. Braun introduced a new line of needle-free connectors with antimicrobial technology designed to reduce infection risks during home infusion therapy.
3. November 2024: Baxter International announced the rollout of an integrated digital platform, “Baxter CareLink,” enabling real-time infusion data tracking and telehealth support for patients receiving home chemotherapy.